Atricure, Inc. (NASDAQ: ATRC) has reported its preliminary financial results for the fourth quarter and full year of 2024, and also provided its financial outlook for 2025. The company announced that its preliminary, unaudited revenue for the fourth quarter of 2024 is expected to be $124.3 million, reflecting a growth of approximately 17% over the fourth quarter of 2023.
In the U.S., revenue is expected to be $101.6 million, indicating a growth of approximately 14%, while international revenue is expected to be $22.7 million, representing an increase of approximately 28% over the same period in 2023. This growth was driven by strong performance in cryosphere® devices for pain management, atriclip® devices in open chest procedures, and the encompass® clamp.
For the full year of 2024, Atricure expects its preliminary, unaudited revenue to be $465.3 million, showing a growth of approximately 17% over the full year of 2023. The company had previously communicated that it expects full-year 2024 positive adjusted EBITDA of approximately $26 million to $29 million and full-year 2024 adjusted loss per share of approximately $0.74 to $0.80.
Looking ahead to 2025, management projects revenue of approximately $517 million to $527 million and full-year 2025 positive adjusted EBITDA of approximately $40 million to $44 million, with modest cash flow generation expected for the full year.
Atricure will also be hosting an analyst & investor day at its headquarters in Mason, Ohio, on Wednesday, March 26, 2025. The company's President and CEO, Michael Carrel, expressed excitement about the upcoming event and emphasized the team's focus on driving growth, innovation, market expansion, and increasing profitability in the year ahead.
Following these announcements, the company's shares moved 9.0%, and are now trading at a price of $34.23. For the full picture, make sure to review AtriCure's 8-K report.
